Setback for Medtronic in ongoing patent dispute with Johnson & Johnson
This article was originally published in Clinica
The US Supreme Court refused to hear Medtronic's appeal over a patent infringement ruling in favour of Johnson & Johnson on February 23. At stake is $271.1m in damages that, as it stands, Medtronic is required to pay to its rival. However, the Supreme Court's decision does not conclude the dispute, and the case is to be reviewed in a district court next month.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.